- Two new independent non-executive directors added to Board with
- Dr. Mal Eutick, OAM appointed independent non-executive Chairman
BRISBANE, Australia, March 4 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced the appointment of John Lee and Robert Williamson to the Company's Board as independent non-executive directors following an extensive search as previously announced. Further, the Board appointed Dr. Mal Eutick as independent non-executive Chairman. Mr. Stephen Chang becomes a non-executive director.
These additions and changes strengthen and focus the Board's expertise
as Progen embarks on its next stage of growth with the continued
development and commercialization of PI-88 and the recently acquired
epigenetics platform (the CellGate acquisition).
A summary of the recent appointees to the Board follow:
-- Mr. John Lee. Independent non-executive director. Investor relations
expert, Australian and US management and Board experience, including
directorships with several other biotech companies.
-- Mr. Robert Williamson. Independent non-executive director.
Considerable US biotechnology experience in the areas of business,
finance and drug development.
Dr. Mal Eutick, currently an independent non-executive director becomes Chairman with the stepping down of Stephen Chang as previously announced. Dr. Eutick has extensive Board experience in the healthcare industry and development of pharmaceutical businesses including founding Phebra (formerly Pharmalab), a critical medicine drug company.
"John Lee's considerable knowledge of global financial markets will be
invaluable to Progen," said Progen's newly appointed Chairman, Dr. Mal
Eutick. "Over the years, he has developed deep relationships in the
financial and investor community, which will enhance shareho
|SOURCE Progen Pharmaceuticals Limited|
Copyright©2008 PR Newswire.
All rights reserved